루닛 둜고

루닛 (328130) μ£Όκ°€ 및 μ’…λͺ© 정보

루닛 μ£Όκ°€ 및 핡심 정보

ν˜„μž¬κ°€ 및 핡심 투자 정보
ν•­λͺ© κ°’
ν˜„μž¬κ°€ 13,640 원
λ³€λ™λŸ‰ β–Ό 500 원
변동λ₯  -3.54%
κΈ°μ€€ μ‹œκ°
거래 ꡬ뢄 μ •κ·œμž₯
μ‹œμž₯ KOSDAQ
κ±°λž˜μ†Œ KRX Β· NXT 거래 κ°€λŠ₯
μ‹œκ°€ 13,400 원
κ³ κ°€ 13,980 원
μ €κ°€ 12,340 원
52μ£Ό λ²”μœ„ 8,180 원 ~ 24,550 원
κ±°λž˜λŸ‰ 3,089,666
κ±°λž˜λŒ€κΈˆ 40,852,727,915 원
μ‹œκ°€μ΄μ•‘ 1μ‘° 528얡원
PER -25.25λ°°
PBR 8.75λ°°
EPS -762.9625 원
μ—…μ’… μ†Œν”„νŠΈμ›¨μ–΄

일별 μ£Όκ°€

κ³Όκ±° 일별 μ£Όκ°€ 정보
λ‚ μ§œ μ‹œκ°€ κ³ κ°€ μ €κ°€ μ’…κ°€ κ±°λž˜λŸ‰ κ±°λž˜λŒ€κΈˆ
2026.10.29 15,450 16,290 14,040 15,130 4,517,486 67,927,369,675
2026.10.30 14,980 16,150 14,610 15,400 4,108,233 64,148,413,585
2026.11.02 15,270 16,050 14,665 16,000 1,612,960 24,808,742,195
2026.11.03 15,570 15,900 14,520 15,220 2,061,758 31,539,833,475
2026.11.04 14,870 15,540 13,840 14,330 1,771,025 25,814,253,495
2026.11.05 14,700 15,730 14,340 14,710 2,402,609 35,965,239,480
2026.11.06 13,280 16,050 13,150 15,470 3,589,373 55,043,000,000
2026.11.09 15,070 17,100 14,650 16,290 3,561,553 58,455,161,070
2026.11.10 16,200 17,570 15,930 16,780 2,322,978 39,175,592,360
2026.11.11 16,810 16,950 13,680 13,890 4,556,574 68,216,058,895

νšŒμ‚¬ 정보

κΈ°μ—…μˆœμœ„ μ£Όμ‹μˆ˜ 외ꡭ인 비쀑 μ‚°μ—…κ΅° μ„ΈλΆ€ μ‚°μ—…κ΅°
KOSDAQ 71μœ„ 74,458,180 6.54% IT/ICT μ†Œν”„νŠΈμ›¨μ–΄

κΈ°μ—… κ°œμš”

루닛은 2013λ…„ 08μ›” 23일 섀립 λ˜μ—ˆμœΌλ©°, μƒν˜Έλ₯Ό ν΄λ””μ—μ„œ ν˜„μž¬μ˜ μ£Όμ‹νšŒμ‚¬ λ£¨λ‹›μœΌλ‘œ λ³€κ²½, AIν—¬μŠ€μΌ€μ–΄ 사업을 μ˜μœ„ν•˜κ³  μžˆλ‹€. μ£Όμš” λ§€μΆœμ€ Lunit INSIGHT, Lunit SCOPE μ œν’ˆ νŒλ§€μ—μ„œ λ°œμƒν•˜κ³  μžˆλ‹€. λ‹Ήμ‚¬λŠ” λ”₯λŸ¬λ‹ κΈ°μˆ μ„ 톡해 μΈκ°„μ˜ μ‹œκ°μ  ν•œκ³„λ₯Ό λ³΄μ™„ν•˜λŠ” νŒλ… 보쑰 μ†”λ£¨μ…˜μ„ κ°œλ°œν•˜μ—¬ μƒμš©ν™”ν•˜μ˜€μœΌλ©°, μ œμ•½νšŒμ‚¬, μž„μƒμ‹œν—˜ μ „λ¬ΈκΈ°κ΄€, 진단검사 μˆ˜νƒκΈ°κ΄€ 등을 λŒ€μƒμœΌλ‘œ ν•˜λŠ” μ—°κ΅¬μš© 판맀λ₯Ό 톡해 μ„±μž₯ 동λ ₯을 ν™•λ³΄ν•˜κ³ , 의료기기 ν—ˆκ°€λ₯Ό νšλ“ν•˜μ—¬ μž„μƒμš© 판맀둜 μ‹œμž₯을 ν™•λŒ€ν•  μ˜ˆμ •μ΄λ‹€.

κ΄€λ ¨ ν…Œλ§ˆ

  • AI : λ”₯λŸ¬λ‹ 기반 의료 인곡지λŠ₯(AI) 업체 λ”₯λŸ¬λ‹ κΈ°μˆ μ„ 톡해 μΈκ°„μ˜ μ‹œκ°μ  ν•œκ³„λ₯Ό λ³΄μ™„ν•˜λŠ” νŒλ… 보쑰(AIassisted detection) μ†”λ£¨μ…˜μ„ κ°œλ°œν•˜μ—¬ μƒμš©ν™”ν–ˆμœΌλ©°, μ£Όμš” μ œν’ˆ 및 μ„œλΉ„μŠ€λ‘œλŠ” μ•” 진단 κ΄€λ ¨ μ˜μƒ νŒλ… 보쑰 μ†”λ£¨μ…˜μΈ Lunit INSIGHT와 μ•” 치료 κ΄€λ ¨ 이미징 λ°”μ΄μ˜€λ§ˆμ»€ μ†”λ£¨μ…˜μΈ Lunit SCOPE 등이 있음
  • 의료기기 : κΈ€λ‘œλ²Œ μ˜λ£ŒκΈ°κ΄€ 3,600κ³³ μ΄μƒμ—μ„œ AI μ˜μƒ μ†”λ£¨μ…˜ μ‚¬μš©
  • AI의료 : μ•” 진단 μ˜μƒ νŒλ… AI와 μœ λ°©μ•” κ²€μ§„ μ†Œν”„νŠΈμ›¨μ–΄ 보유

AI예츑

AIμ˜ˆμΈ‘κΈ°λŠ” 이 μ’…λͺ©μ„ κ°•λ ₯맀도 Β· 맀도 Β· 쀑립 Β· 맀수 Β· κ°•λ ₯맀수 둜 μ˜ˆμΈ‘ν–ˆμ–΄μš”.

멀버십 ν”Œλžœμ„ κ΅¬λ…ν•˜λ©΄ μ˜ˆμƒ μ£Όκ°€ μ‹œλ‚˜λ¦¬μ˜€μ™€ AI의 투자의견, λͺ©ν‘œΒ·μ†μ ˆκ°€, AIκ°€ μ°Έκ³ ν•œ 차트 νŒ¨ν„΄λ“€μ„ 확인할 수 μžˆμŠ΅λ‹ˆλ‹€.

μ§€ν‘œλΆ„μ„

수읡λ₯  1μœ„ λ§€λ§€μ „λž΅μ€ 이 μ’…λͺ©μ„ 맀수 Β· 맀도 Β· 보유 Β· 관망 μ€‘μ΄μ—μš”.

멀버십 ν”Œλžœμ„ κ΅¬λ…ν•˜λ©΄ 수읡λ₯  1μœ„ λ§€λ§€μ „λž΅μ˜ λ§€λ§€ μ‹œμ μ„ ν™•μΈν•˜κ³  λ‹€μŒ μ‹ ν˜Έλ₯Ό μ•Œλ¦ΌμœΌλ‘œ λ°›μ•„λ³Ό 수 μžˆμŠ΅λ‹ˆλ‹€.

μ΅œμ‹  κ΄€λ ¨ λ‰΄μŠ€

의료 인곡지λŠ₯(AI) κΈ°μ—… 루닛이 3λΆ„κΈ° 맀좜이 μ—°κ²° κΈ°μ€€ 222μ–΅1500λ§Œμ›μœΌλ‘œ μ „λ…„ 동기 λŒ€λΉ„ 13% μ¦κ°€ν–ˆλ‹€κ³  12일 λ°ν˜”λ‹€. μ˜μ—…μ†μ‹€μ€ 106μ–΅8500λ§Œμ›μœΌλ‘œ μ „λ…„(215μ–΅5600λ§Œμ›)보닀 50.4% κ°μ†Œν–ˆλ‹€. λ£¨λ‹›μ˜ 맀좜 λŒ€λΆ€λΆ„μ΄ ν•΄μ™Έμ—μ„œ λ°œμƒν•˜λŠ” κ°€μš΄λ°, 원화 강세에도 λΆˆκ΅¬ν•˜κ³  3λΆ„κΈ° κΈ°μ€€ μ—­λŒ€ μ΅œλŒ€ λ§€μΆœμ„ μ˜¬λ Έλ‹€. λ£¨λ‹›μ˜ 3λΆ„κΈ° ν•΄μ™Έ λ§€μΆœμ€ μ „λ…„ 동기 λŒ€λΉ„ 15%, 직전 λΆ„κΈ° λŒ€λΉ„ 3% λŠ˜μ—ˆλ‹€. μ•” κ²€μ§„ μ‚¬μ—…λΆ€λ¬Έμ˜ 3λΆ„κΈ° λˆ„μ  λ§€μΆœμ€ 631μ–΅7000λ§Œμ›μœΌλ‘œ μ „λ…„ 동기 λŒ€λΉ„ 20% μ„±μž₯ν–ˆλ‹€. 뢁미 μ§€μ—­ 맀좜이 μ „μ²΄μ˜ 71%λ₯Ό μ°¨μ§€ν–ˆλ‹€. λ―Έκ΅­ 사업을 λ‹΄λ‹Ήν•˜λŠ” μžνšŒμ‚¬ 루닛 인터내셔널(μ˜› 볼파라)의 κ΅¬λ…ν˜• μ†Œν”„νŠΈμ›¨μ–΄(SaaS) 맀좜과 κΈ°μ‘΄ 고객사λ₯Ό λŒ€μƒμœΌλ‘œ ν•œ μ œν’ˆ κ΅μ°¨νŒλ§€κ°€ 맀좜 증가에 영ν–₯을 λ―Έμ³€λ‹€λŠ” μ„€λͺ…이닀....

[λ°μΌλ¦¬ν•œκ΅­ μ‹¬μš°λ―Ό 기자] 의료 인곡지λŠ₯ κΈ°μ—… 루닛이 올 3λΆ„κΈ° μ˜μ—…μ†μ‹€μ„ μ „λ…„ 동기 λŒ€λΉ„ 절반 μˆ˜μ€€μœΌλ‘œ 쀄이며 μˆ˜μ΅μ„± κ°œμ„  흐름을 이어갔닀.루닛은 μ˜¬ν•΄ 3λΆ„κΈ° μ˜μ—…μ†μ‹€μ΄ 107μ–΅μ›μœΌλ‘œ μ „λ…„ 동기 λŒ€λΉ„ 50% κ°œμ„ λλ‹€κ³  12일 κ³΅μ‹œν–ˆλ‹€. μƒκ°μ „μ˜μ—…μ΄μ΅(EBITDA) κΈ°μ€€ 손싀은 35μ–΅μ›μœΌλ‘œ 77% κ°œμ„ λμœΌλ©°, λ§€μΆœμ€ 222μ–΅μ›μœΌλ‘œ 13% μ¦κ°€ν–ˆλ‹€.3λΆ„κΈ° λˆ„μ  μ˜μ—…μ†μ‹€μ€ 396μ–΅μ›μœΌλ‘œ μ•½ 38% κ°œμ„ λλ‹€. EBITDA 손싀은 μ „λ…„ 동기 λŒ€λΉ„ 59% κ°œμ„ λμœΌλ©°, λ§€μΆœμ€ μ „λ…„ 동기 λŒ€λΉ„ 680μ–΅μ›μœΌλ‘œ μ „λ…„ 동기 λŒ€λΉ„ 20% λŠ˜μ—ˆλ‹€.νšŒμ‚¬μΈ‘

의료 인곡지λŠ₯(AI) κΈ°μ—… 루닛(328130)이 해외사업 μ„±μž₯에 νž˜μž…μ–΄ 3λΆ„κΈ° λˆ„μ  κΈ°μ€€ μ—­λŒ€ μ΅œλŒ€ λ§€μΆœμ„ μ˜¬λ Έλ‹€. λΉ„μš©μ„ μ€„μ΄λ©΄μ„œ 3λΆ„κΈ° μƒκ°μ „μ˜μ—…μ΄μ΅(EBITDA) κΈ°μ€€ 손싀은 14개 λΆ„κΈ° λ§Œμ— κ°€μž₯ μ μ—ˆλ‹€. 루닛은 μ˜¬ν•΄ 3λΆ„κΈ°κΉŒμ§€ μ—°κ²° κΈ°μ€€ λˆ„μ  맀좜이 679μ–΅

[인텔 AI μ„œλ°‹ μ„œμšΈ 2026] 인텔이 ν•œκ΅­μ˜ λ°˜λ„μ²΄Β·λ‘œλ΄‡ μ‚°μ—… 경쟁λ ₯을 λ°”νƒ•μœΌλ‘œ μ†Œλ²„λ¦° AI(인곡지λŠ₯)와 μ—£μ§€ AI λΆ„μ•Όμ—μ„œ μƒˆλ‘œμš΄ 사업 기회λ₯Ό μ°Ύκ² λ‹€λŠ” ꡬ상을 λ°ν˜”λ‹€. ν•œκ΅­ κΈ°μ—…μ˜ 기술과 μ œν’ˆμ΄ 세계 μ‹œμž₯으둜 ν™•μ‚°ν•  수 μžˆλ„λ‘ ν˜‘λ ₯ν•˜κ² λ‹€λŠ” 것이닀. μ‚°ν† μ‹œ λΉ„μŠ€μ™€λ‚˜νƒ„ 인텔 μ•„μ‹œμ•„νƒœν‰μ–‘Β·μΌλ³Έ μ§€μ—­ μ˜μ—…κ΄€λ¦¬κ·Έλ£Ή 총괄 뢀사μž₯은 12일 μ„œμšΈ 강남ꡬ μ½”μ—‘μŠ€μ—μ„œ μ—΄λ¦° '인텔 AI μ„œλ°‹ μ„œμšΈ 2026' κ°œνšŒμ‚¬μ—μ„œ "ν•œκ΅­μ—μ„œ μ‹€μ§ˆμ μΈ λ³€ν™”λ₯Ό λ§Œλ“€μ–΄λ‚Ό 수 μžˆλŠ” 핡심 λΆ„μ•Όλ‘œ μ†Œλ²„λ¦° AI와 κ°œμΈν™” AI 두 κ°€μ§€λ₯Ό κΌ½κ³  μ‹Άλ‹€"κ³  λ°ν˜”λ‹€. κ·ΈλŠ” "μ§„μ •ν•œ μ†Œλ²„λ¦° AIλ₯Ό κ΅¬ν˜„ν•˜κΈ° μœ„ν•΄ λͺ¨λ“  인프라 μš”μ†Œλ₯Ό 직접 ν†΅μ œν•  ν•„μš”λŠ” μ—†λ‹€"λ©° "각ꡭ이 μžμ‹ λ§Œμ˜ 강점을 살릴 수 μžˆλŠ” μ˜μ—­μ„ μ°Ύμ•„μ•Ό ν•œλ‹€"κ³  κ°•μ‘°ν–ˆλ‹€. 이어 "ν•œκ΅­μ€ 자체 κ±°λŒ€μ–Έμ–΄λͺ¨λΈ(LLM)을 λ³΄μœ ν•˜κ³  있고 λ©”λͺ¨λ¦¬ λΆ„μ•Όμ—μ„œλ„ 핡심적인 μœ„μΉ˜μ— μžˆλ‹€"λ©° "각ꡭ의 ν™˜κ²½μ— λ§žλŠ” ν™•μž₯ κ°€λŠ₯ν•œ 인프라λ₯Ό ꡬ좕할 κΈ°νšŒκ°€ μžˆλ‹€"κ³  μ„€λͺ…ν–ˆλ‹€....

μ‹€μ ν˜„ν™©

λ§€μΆœμ•‘

κΈ°κ°„ ꡬ뢄 λ§€μΆœμ•‘ μ¦κ°€μœ¨
2025 μ—°κ°„ (YoY) 83,129,295,404 53.43%
2024 μ—°κ°„ (YoY) 54,179,663,335 116.03%
2023 μ—°κ°„ (YoY) 25,080,238,712 80.88%
2022 μ—°κ°„ (YoY) 13,865,732,000 108.85%
2026.2Q λΆ„κΈ° (QoQ) 21,813,709,916 -8.93%
2026.1Q λΆ„κΈ° (QoQ) 23,952,343,774 -9.53%
2025.4Q λΆ„κΈ° (QoQ) 26,476,422,178 35.25%
2025.3Q λΆ„κΈ° (QoQ) 19,575,722,788 9.52%

μ˜μ—…μ΄μ΅

κΈ°κ°„ ꡬ뢄 μ˜μ—…μ΄μ΅ μ¦κ°€μœ¨
2025 μ—°κ°„ (YoY) -83,103,910,311 -22.80%
2024 μ—°κ°„ (YoY) -67,672,567,880 -60.30%
2023 μ—°κ°„ (YoY) -42,216,718,386 16.65%
2022 μ—°κ°„ (YoY) -50,650,984,000 -210.83%
2026.2Q λΆ„κΈ° (QoQ) -15,368,887,353 -13.06%
2026.1Q λΆ„κΈ° (QoQ) -13,593,188,215 31.25%
2025.4Q λΆ„κΈ° (QoQ) -19,772,798,612 8.27%
2025.3Q λΆ„κΈ° (QoQ) -21,555,812,087 -2.11%

순이읡

κΈ°κ°„ ꡬ뢄 순이읡 μ¦κ°€μœ¨
2025 μ—°κ°„ (YoY) -47,389,679,756 42.50%
2024 μ—°κ°„ (YoY) -82,420,863,344 -123.98%
2023 μ—°κ°„ (YoY) -36,798,251,578 5.93%
2022 μ—°κ°„ (YoY) -39,117,906,000 -153.09%
2026.2Q λΆ„κΈ° (QoQ) -23,557,162,142 -32.27%
2026.1Q λΆ„κΈ° (QoQ) -17,809,588,938 45.34%
2025.4Q λΆ„κΈ° (QoQ) -32,581,949,764 -279.77%
2025.3Q λΆ„κΈ° (QoQ) 18,124,554,298 151.84%

μˆœλ§€μˆ˜λŸ‰

개인: -153,752

κΈ°κ΄€: 95,212

외인: 56,152

λˆ„μ  μˆœλ§€μˆ˜λŸ‰

개인: 2,587,105

κΈ°κ΄€: 2,052,690

외인: -4,492,920

순맀수

λ‚ μ§œ 개인 κΈ°κ΄€ 외인
2026-11-12 -153,752 95,212 56,152
2026-11-11 1,226,731 -1,056,041 -175,270
2026-11-10 -119,530 168,032 -53,339
2026-11-09 -225,133 344,937 -123,569
2026-11-06 -419,015 376,690 37,585
2026-11-05 -91,307 210,550 -103,800
2026-11-04 -66,195 174,673 -104,999
2026-11-03 13,262 225,046 -264,612
2026-11-02 -83,764 99,966 4,951
2026-10-30 -232,098 285,270 -79,661
2026-10-29 435,076 144,984 -588,409
2026-10-28 -132,323 84,146 50,648
2026-10-27 -93,383 84,496 2,804
2026-10-26 -268,852 289,657 187,190
2026-10-23 -37,482 68,151 -30,639
2026-10-22 -48,968 -19,635 68,199
2026-10-21 395,127 -89,128 -305,220
2026-10-20 40,371 67,350 -94,584
2026-10-19 -269,068 436,149 -167,542
2026-10-16 -276,066 163,047 132,267
2026-10-15 79,466 10,820 -128,032

λˆ„μ  순맀수

λ‚ μ§œ 개인 κΈ°κ΄€ 외인
2026-11-12 -326,903 2,164,372 -1,679,880
2026-11-11 -173,151 2,069,160 -1,736,032
2026-11-10 -1,399,882 3,125,201 -1,560,762
2026-11-09 -1,280,352 2,957,169 -1,507,423
2026-11-06 -1,055,219 2,612,232 -1,383,854
2026-11-05 -636,204 2,235,542 -1,421,439
2026-11-04 -544,897 2,024,992 -1,317,639
2026-11-03 -478,702 1,850,319 -1,212,640
2026-11-02 -491,964 1,625,273 -948,028
2026-10-30 -408,200 1,525,307 -952,979
2026-10-29 -176,102 1,240,037 -873,318
2026-10-28 -611,178 1,095,053 -284,909
2026-10-27 -478,855 1,010,907 -335,557
2026-10-26 -385,472 926,411 -338,361
2026-10-23 -116,620 636,754 -525,551
2026-10-22 -79,138 568,603 -494,912
2026-10-21 -30,170 588,238 -563,111
2026-10-20 -425,297 677,366 -257,891
2026-10-19 -465,668 610,016 -163,307
2026-10-16 -196,600 173,867 4,235
2026-10-15 79,466 10,820 -128,032

μžμ‚° λΉ„μœ¨

μžμ‚°μ΄κ³„ λΆ€μ±„λΉ„μœ¨ μžλ³ΈλΉ„μœ¨
545,270,658,294 39.18% 60.82%

맀좜 ꡬ성

ꡬ성 μš”μ†Œ λΉ„μœ¨
μ†Œν”„νŠΈμ›¨μ–΄ [Cancer Screening] 71.85%
μš©μ—­ [Oncology] 24.38%
기타 [Oncology] 2.32%
기타 [Cancer Screening] 1.18%
기타 0.14%
μƒν’ˆ 0.13%

곡맀도 ν˜„ν™©

졜근 곡맀도 κ±°λž˜λŸ‰: 251,379 (2.93%)

졜근 곡맀도 μž”κ³ : 4,268,748 (5.73%)

곡맀도 κ±°λž˜λŸ‰

λ‚ μ§œ μ’…κ°€ κ³΅λ§€λ„λŸ‰ 곡맀도비쀑
2026-11-11 13,890 251,379 2.93%
2026-11-10 16,780 198,857 4.76%
2026-11-09 16,290 302,233 4.50%
2026-11-06 15,470 299,013 4.73%
2026-11-05 14,710 222,572 5.29%
2026-11-04 14,330 181,293 5.37%
2026-11-03 15,220 407,069 11.42%
2026-11-02 16,000 186,172 6.14%
2026-10-30 15,400 249,677 3.26%
2026-10-29 15,130 437,425 5.42%
2026-10-28 14,760 200,094 4.46%
2026-10-27 15,070 326,246 2.75%
2026-10-26 14,690 213,233 2.47%
2026-10-23 11,240 90,117 10.53%
2026-10-22 11,040 85,667 8.52%
2026-10-21 11,670 299,858 15.21%
2026-10-20 12,780 140,618 9.18%
2026-10-19 12,900 163,068 5.96%
2026-10-16 12,050 136,683 6.95%
2026-10-15 10,730 114,581 7.28%
2026-10-14 11,940 222,518 10.40%

곡맀도 μž”κ³ 

λ‚ μ§œ μ’…κ°€ 곡맀도 μž”κ³  곡맀도 비쀑
2026-11-09 16,290 4,268,748 5.73%
2026-11-06 15,470 4,144,065 5.57%
2026-11-05 14,710 4,109,304 5.52%
2026-11-04 14,330 4,108,933 5.52%
2026-11-03 15,220 3,982,989 5.35%
2026-11-02 16,000 3,530,182 4.74%
2026-10-30 15,400 3,371,471 4.53%
2026-10-29 15,130 3,337,087 4.48%
2026-10-28 14,760 2,715,793 3.65%
2026-10-27 15,070 2,715,028 3.65%
2026-10-26 14,690 2,573,926 3.46%
2026-10-23 11,240 2,888,620 3.88%
2026-10-22 11,040 2,852,462 3.83%
2026-10-21 11,670 2,918,460 3.92%
2026-10-20 12,780 2,582,242 3.47%
2026-10-19 12,900 2,434,145 3.27%
2026-10-16 12,050 2,283,167 3.07%
2026-10-15 10,730 2,403,572 3.23%
2026-10-14 11,940 2,240,597 3.01%
2026-10-13 11,480 1,993,111 2.68%
2026-10-12 11,010 1,999,028 2.68%

μ—…μ’… λ‚΄ 비ꡐ

μ†Œν”„νŠΈμ›¨μ–΄ μ—…μ’…(79개) μ—°κ°„ κΈ°μ€€

ν•­λͺ© ν˜„μž¬ μ’…λͺ© μ—…μ’… 평균 μ—…μ’… λ‚΄ μˆœμœ„
μ‹œκ°€μ΄μ•‘ 12,538.758 1,058.46 1μœ„
PER(졜근4λΆ„κΈ°) -18.105 -7.27 70μœ„
PBR 3.767 27,863.09 6μœ„
ROE(졜근4λΆ„κΈ°) -31.353 -5.29 68μœ„
λ°°λ‹Ήμˆ˜μ΅λ₯ (μ΅œκ·Όμ—°λ„) - - -μœ„
μ˜μ—…μ΄μ΅λ₯ (μ΅œκ·Όμ—°λ„) -99.969 -21.72 71μœ„
순이읡λ₯ (μ΅œκ·Όμ—°λ„) -57.007 -25.53 68μœ„
λΆ€μ±„λΉ„μœ¨(μ΅œκ·Όμ—°λ„) 169.158 76.03 9μœ„
λ§€μΆœμ•‘(μ΅œκ·Όμ—°λ„) 831.293 3,102.93 19μœ„
μ˜μ—…μ΄μ΅(μ΅œκ·Όμ—°λ„) -831.039 220.65 77μœ„
λ‹ΉκΈ°μˆœμ΄μ΅(μ΅œκ·Όμ—°λ„) -473.897 165.86 77μœ„